
    
      This Phase 3, prospective, randomized, double-blinded, placebo-controlled, multi-center study
      will enroll approximately 210 subjects at up to 70 sites in the United States. Participation
      will consist of a Screening Period, followed by a minimum 12-month Treatment Period. SC411 is
      administered orally as a soft gel mini capsule.

      This study will enroll subjects aged ≥5 to ≤17 years who have a diagnosis of SCD that
      includes the phenotypes hemoglobin SS homozygous (HbSS), hemoglobin SC (HbSC), and hemoglobin
      S/β°-thalassemia (HbS/ β°-thalassemia); and have had at least 2 but no more than 10
      documented SCC events (as defined above) within 12 months prior to the Screening Visit.
    
  